Economic analysis of investment priorities for measles control.
J Infect Dis
; 170 Suppl 1: S56-62, 1994 Nov.
Article
en En
| MEDLINE
| ID: mdl-7930754
ABSTRACT
An investment strategy in measles control should strike an appropriate balance among three areas implementation of existing vaccination programs with existing technology, operations research to improve the use of existing technology, and vaccine development. As a benchmark, the existing Schwarz vaccine costs approximately $17 per DALY (disability-adjusted life year), already making it one of the most cost-effective health interventions in developing countries. National measles vaccination campaigns, such as Brazil's, are a promising extension of this technology. Operations research is indicated to study the organization of campaigns, supplying and delivering vitamin A to hospitalized children, and other issues. The development and application of an early one-dose measles vaccine would be particularly cost-effective ($5 per DALY), as it could avoid the costs to families and health institutions of the separate visit at 9 months now required for measles vaccination. All three areas present opportunities for cost-effective investments and deserve a place in an investment strategy.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Vacuna Antisarampión
/
Vacunación
/
Sarampión
Tipo de estudio:
Health_economic_evaluation
Límite:
Child, preschool
/
Humans
/
Infant
/
Newborn
Idioma:
En
Año:
1994
Tipo del documento:
Article